Physician profile
Ajay Kumar
NPI 1962426817
$4,777.98
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $482 · 2021: $2,232 · 2022: $545 · 2023: $305 · 2024: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,197.38 | 2019-2024 | Ozempic, Rybelsus |
| Bioness INC | $427.47 | 2021 | |
| Lilly USA, LLC | $379.55 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $324.40 | 2019-2024 | Evenity, Prolia |
| Abbott Laboratories | $229.22 | 2019-2024 | Freestyle Libre 3 |
| Insulet Corporation | $178.48 | 2019-2024 | Omnipod |
| Sanofi-Aventis U.S. LLC | $130.32 | 2019-2023 | |
| Tandem Diabetes Care, INC. | $126.56 | 2019 | |
| Dexcom, INC. | $119.25 | 2019-2024 | Dexcom G6 Transmitter |
| Genzyme Corporation | $90.00 | 2019 | |
| Medtronic, INC. | $87.24 | 2021-2023 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.77 | 2022-2024 | Synjardy, Jardiance, Tradjenta |
| Medtronic Minimed, INC. | $62.43 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $58.51 | 2022-2024 | |
| Lifescan, INC. | $43.71 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $38.67 | 2019-2024 | |
| Amarin Pharma, INC. | $29.77 | 2019-2020 | |
| Valeritas, INC. | $28.39 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.53 | 2020 | |
| Roche Diabetes Care, INC. | $18.66 | 2019 | |
| Mannkind Corporation | $18.03 | 2023 | Afrezza |
| Senseonics, Incorporated | $18.00 | 2019 | |
| Antares Pharma, INC. | $17.41 | 2019 | |
| Ibsa Pharma INC. | $17.12 | 2020 | |
| Horizon Therapeutics Plc | $13.86 | 2022 | |
| Tolmar, INC. | $13.70 | 2023 | |
| Abbvie INC. | $11.54 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.